Related references
Note: Only part of the references are listed.Comparative effectiveness and safety of direct oral anticoagulants compared to warfarin in morbidly obese patients with acute venous thromboembolism: systematic review and a meta-analysis
Mohamed Nabil Elshafei et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2021)
Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data
Olivia S. Costa et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2021)
Direct Oral Anticoagulant Concentrations in Obese and High Body Weight Patients: A Cohort Study
Anne Celine Martin et al.
THROMBOSIS AND HAEMOSTASIS (2021)
Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity
Alexander Cohen et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Investigation of Direct-Acting Oral Anticoagulants and the Incidence of Venous Thromboembolism in Patients Weighing >= 120 kg Compared to Patients Weighing <120 kg
Kristin G. Aloi et al.
JOURNAL OF PHARMACY PRACTICE (2021)
Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight
Isaac J. Perales et al.
ANNALS OF PHARMACOTHERAPY (2020)
Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous Thromboembolism
James C. Coons et al.
PHARMACOTHERAPY (2020)
Effectiveness and safety of apixaban and rivaroxaban for acute venous thromboembolism therapy in patients with extremes in bodyweight
Waldemar E. Wysokinski et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2020)
Evidence of impaired dabigatran absorption following laparoscopic Roux-en-Y gastric bypass surgery: the Auckland regional experience (2011-2018)
Brian Grainger et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysis
Victoria Speed et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data
Margarita Kushnir et al.
LANCET HAEMATOLOGY (2019)
Validation of apixaban anti-factor Xa assay and impact of body weight
Suman M. Wasan et al.
THROMBOSIS RESEARCH (2019)
Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs
Alex C. Spyropoulos et al.
THROMBOSIS RESEARCH (2019)
Obesity and cardiovascular disease: revisiting an old relationship
Chrysi Koliaki et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2019)
Impact of BMI on clinical outcomes of NOAC therapy in daily care - Results of the prospective Dresden NOAC Registry (NCT01588119)
L. Tittl et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2018)
Regional Gastrointestinal Absorption of Apixaban in Healthy Subjects
Wonkyung Byon et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2018)
The effect of bariatric surgery on direct-acting oral anticoagulant drug levels
Amihai Rottenstreich et al.
THROMBOSIS RESEARCH (2018)
The effect of bariatric surgery on the direct oral anticoagulant rivaroxaban: the extension study
Dino Kroell et al.
SURGERY FOR OBESITY AND RELATED DISEASES (2018)
Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations
Stefan Willmann et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2018)
Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study
Siavash Piran et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2018)
Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs)
Hakeam A. Hakeam et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2017)
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
J. I. Weitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The impact of body weight on rivaroxaban pharmacokinetics
Sarah J. Barsam et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2017)
Oral Anticoagulant Use After Bariatric Surgery: A Literature Review and Clinical Guidance
Karlyn A. Martin et al.
AMERICAN JOURNAL OF MEDICINE (2017)
Antithrombotic Therapy for VTE Disease CHEST Guideline and Expert Panel Report
Clive Kearon et al.
CHEST (2016)
Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH
K. Martin et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)
Effect of extremes of body weight on drug level in patient treated with standard dose of rivaroxaban for venous thromboembolism; real life experience
D. R. J. Arachchillage et al.
THROMBOSIS RESEARCH (2016)
Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics
Sophie Testa et al.
THROMBOSIS RESEARCH (2016)
Effect of body weight on efficacy and safety of direct oral anticoagulants in the treatment of patients with acute venous thromboembolism: A meta-analysis of randomized controlled trials
Matteo Nicola Dario Di Minno et al.
ANNALS OF MEDICINE (2015)
Meta-analysis on efficacy and safety of new oral anticoagulants for venous thromboembolism prophylaxis in overweight and obese postarthroplasty patients
Ranjan Pathak et al.
BLOOD COAGULATION & FIBRINOLYSIS (2015)
Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule
Dolly A. Parasrampuria et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Real-world variability in dabigatran levels in patients with atrial fibrillation: reply
N. C. Chan et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
Christian T. Ruff et al.
LANCET (2015)
Population Pharmacokinetics and Dose-Exposure Proportionality of Edoxaban in Healthy Volunteers
Ophelia Q. P. Yin et al.
CLINICAL DRUG INVESTIGATION (2014)
The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)
Paul A. Reilly et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects
Vijay V. Upreti et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels
E. M. Hawes et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups
G. F. Pineo et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Pharmacokinetics of rivaroxaban after bariatric surgery: a case report
Adrian Mahlmann et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2013)
Apixaban for Extended Treatment of Venous Thromboembolism
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: A pooled analysis
Bengt I. Eriksson et al.
THROMBOSIS RESEARCH (2012)
Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty
Alexander G. G. Turpie et al.
THROMBOSIS AND HAEMOSTASIS (2011)
Population pharmacokinetics and pharmacodynamics of rivaroxaban - An oral, direct factor Xa inhibitor in patients undergoing major orthopaedic surgery
Wolfgang Mueck et al.
CLINICAL PHARMACOKINETICS (2008)
Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects
Dagmar Kubitza et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Share Paper
